Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes.

Charlene M PrazmaMarco IdzkoJo Anne DouglassArnaud BourdinStephen MallettFrank C AlbersSteven W Yancey

Published in: Journal of asthma and allergy (2021)

Mepolizumab was associated with a trend for reductions in clinically significant exacerbations and improved asthma control versus placebo in patients with severe eosinophilic asthma, irrespective of atopic status or HDM sensitivity.

Keyphrases

chronic obstructive pulmonary disease
lung function
allergic rhinitis
cystic fibrosis
early onset
randomized controlled trial
clinical trial
drug induced
double blind
replacement therapy